Commentary demonstrates neutrophil to lymphocyte ratio predicts survival outcomes in stage II and III colon cancer, suggesting wider clinical adoption for risk assessment.
We read with great interest the article ‘A derived neutrophil to lymphocyte (N/L) ratio predicts clinical outcome in stage II and III colon cancer patients’ by Absenger et al (2013) . They aimed to investigate the effect of the preoperative N/L ratio on time to recurrence and overall survival in patients with stage II and III colon cancer. They concluded that the N/L ratio is an independent prognostic marker in our study cohort including patients with stage II and III colon cancer. The ready availability of this parameter at no additional cost may encourage its wider use in clinical practice in the future. Thank to the authors for their contribution.
No takes yet. Share an insight, caveat, or question.
Balta et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: